Acute administration of clozapine and risperidone altered dopamine metabolism more in rat caudate than in nucleus accumbens: A dose-response relationship

Scientia Pharmaceutica

Volumn 78, Issue 2, 2010, Pages 259-274

  Batool, Farhat ^a   Haleem, Muhammad A ^b   Haleem, Darakhshan J ^a  

^a UNIVERSITY OF KARACHI   (Pakistan)

^b SIR SYED UNIVERSITY OF ENGINEERING AND TECHNOLOGY   (Pakistan)

Author keywords

Atypical antipsychotics; Dopamine D2 receptors; Extrapyramidal side effects; Schizophrenia; Serotonin 1AReceptors

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; CLOZAPINE; DIHYDROXYPHENYLACETIC ACID; HOMOVANILLIC ACID; RISPERIDONE; SEROTONIN; TRYPTOPHAN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CATALEPSY; CAUDATE NUCLEUS; CORPUS STRIATUM; DOPAMINE METABOLISM; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; EXTRAPYRAMIDAL SYNDROME; LOCOMOTION; MALE; NONHUMAN; NUCLEUS ACCUMBENS; RAT;

EID: 77954634390     PISSN: 00368709     EISSN: 22180532     Source Type: Journal    
DOI: 10.3797/scipharm.0907-20     Document Type: Article

References (36)

1. Kuroki T, Nagao N, Nakahara T. Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis. Prog Brain Res. 2008; 172: 199-212. doi:10.1016/S0079-6123(08)00910-2
2. Remington G. Alterations of dopamine and serotonin transmission in schizophrenia. Prog Brain Res. 2008; 172: 117-140. doi:10.1016/S0079-6123(08)00906-0
3. Meltzer HY, Huang M. In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems. Prog Brain Res. 2008; 172: 177-197. doi:10.1016/S0079-6123(08)00909-6
4. Pilowsky LS, Costa DC, Ell PJ, Verhoeff NP, Murray RM, Kerwin RW. D2 dopamine receptor binding in the basal ganglia of antipsychotic-free schizophrenic patients. An 123I-IBZM single photon emission computerized tomography study. Br J Psychiatry. 1994; 164: 16-26. doi:10.1192/bjp.164.1.16
5. Salimi K, Jarskog LF, Lieberman JA. Antipsychotic drugs for first-episode schizophrenia: a comparative review. CNS Drugs. 2009; 23: 837-855. doi:10.2165/11314280-000000000-00000
6. Moran-Gates T, Grady C, Shik Park Y, Baldessarini RJ, Tarazi FI. Effects of risperidone on dopamine receptor subtypes in developing rat brain. Eur Neuropsychopharmacol. 2007; 17: 448-455. doi:10.1016/j.euroneuro.2006.10.004
7. Hertel P, Nomikos GG, Schilström B, Arborelius L, Svensson TH. Risperidone dose-dependently increases extracellular concentrations of serotonin in the rat frontal ortex: role of alpha 2-adrenoceptor antagonism. Neuropsychopharmacology. 1997; 17: 44-55. doi:10.1016/S0893-133X(97)00002-X
8. Bruggeman R, Westerink BH, Timmerman W. Effects of risperidone, clozapine and haloperidol on extracellular recordings of substantia nigra reticulata neurons of the rat brain. Eur J Pharmacol. 1997; 324: 49-56. doi:10.1016/S0014-2999(97)00054-X
9. Newman A, Chaput C, Verriele L. Millan MJ. Clozapine is a partial agonist at cloned human serotonin 5-HT1A receptors. Neuropharmacology. 1996; 35: 119-121. doi:10.1016/0028-3908(95)00170-0
10. Hertel P, Nomikos GG, Iurlo M, Svensson TH. Risperidone: regional effects in vivo on release and metabolism of dopamine and serotonin in the rat brain. Psychopharmacology (Berl). 1996; 124: 74-86. doi:10.1007/BF02245607
11. Szymanski S, Lieberman J, Pollack S, Munne R, Safferman A, Kane J, Kronig M, Cooper T. The dopamine-serotonin relationship in clozapine response. Psychopharmacology. 1993; 112 (1 Suppl): S85-S89. doi:10.1007/BF02245011
12. Bishara D, Taylor D. Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability. Drugs. 2008; 68: 2269-2292. doi:10.2165/0003495-200868160-00002
13. Kerwin RW. The new atypical antipsychotics. A lack of extrapyramidal side-effects and new routes in schizophrenia research. Br J Psychiatry. 1994; 164: 141-148. doi:10.1192/bjp.164.2.141
14. Xiberas X, Martinot JL, Mallet L, Artiges E, Loc'H C, Mazière B, Paillère-Martinot ML. Extrastriatal and striatal D2 dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia. Br J Psychiatry. 2001; 179: 503-508. doi:10.1192/bjp.179.6.503
15. Nyberg S, Farde L, Eriksson L, Halldin C, Eriksson B. 5-HT2 and D2 dopamine receptor occupancy in the living human brain. A PET study with risperidone. Psychopharmacology. 1993; 110: 265-272. doi:10.1007/BF02251280
16. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009; 373 (9657): 31-41. doi:10.1016/S0140-6736(08)61764-X
17. Kasper S, Tauscher J, Küfferle B, Barnas C, Hesselmann B, Asenbaum S, Podreka I, Brücke, T. Sertindole and dopamine D2 receptor occupancy in comparison to risperidone, clozapine and haloperidol - a 123I-IBZM SPECT study. Psychopharmacology. 1998; 136: 367-373. doi:10.1007/s002130050579
18. Haleem DJ, Batool F, Khan NH, Kamil N, Ali O, Saify ZS, Haleem MA. Differences in the effects of haloperidol and clozapine on brain serotonin and dopamine metabolism and on tests related to extrapyramidal functions in rats. Med Sci Monit. 2002; 8: BR354-BR361. PMid:12218936
19. Batool F, Ahmed S, Haleem DJ. Dietary supplementations of amino acids: evidence for enhanced serotonergic functions following haloperidol withdrawal in rat medial prefrontal cortex. J Coll Physicians Surg Pak. 2009; 19: 139-145. PMid:19268010
20. Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D1, D2 and serotonin2 pKi values. J Pharmacol Exp Ther. 1989; 251: 238-246. PMid:2571717
21. Konradi C, Heckers S. Antipsychotic drugs and neuroplasticity: insights into the treatment and neurobiology of schizophrenia. Biol Psychiatry. 2001; 50: 729-742. doi:10.1016/S0006-3223(01)01267-7
22. Wadenberg ML, Kapur S, Soliman A, Jones C, Vaccarino F. Dopamine D2 receptor occupancy predicts catalepsy and the suppression of conditioned avoidance response behavior in rats. Psychopharmacology. 2000; 150: 422-429. doi:10.1007/s002130000466
23. Clow A, Theodorou A, Jenner P, Marsden CD. Changes in rat striatal dopamine turnover and receptor activity during one year neuroleptic administration. Eur J Pharmacol. 1980; 63: 135-144. doi:10.1016/0014-2999(80)90437-9
24. Bigliani V, Mulligan RS, Acton PD, Visvikis D, Ellm PJ, Stephenson C, Kerwin RW, Pilowsky LS. In vivo occupancy of striatal and temporal cortical D2/D3 dopamine receptors by typical antipsychotic drugs. [123I] epidepride single photon emission tomography (SPET) study. Br J Psychiatry. 1999; 175: 231-238. doi:10.1192/bjp.175.3.231
25. Farde L, Wiesel FA, Nordström AL, Sedvall G. D1 and D2 dopamine receptor occupancy during treatment with conventional and atypical neuroleptics. Psychopharmacology. 1989; 99: S28-S31. doi:10.1007/BF00442555
26. Farde L, Wiesel FA, Stone-Elander S, Halldin C, Nordström AL, Hall H, Sedvall G. D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C] raclopride. Arch Gen Psychiatry. 1990; 47: 213-219. PMid:1968328
27. Bressan RA, Erlandsson K, Jones HM, Mulligan RS, Ell PJ, Pilowsky LS. Optimizing limbic selective D2/D3 receptor occupancy by risperidone: a [123I]-epidepride SPET study. J Clin Psychopharmacol. 2003; 23: 5-14. doi:10.1097/00004714-200302000-00002
28. Kapur S, Seeman P. Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics?: A new hypothesis. Am J Psychiatry. 2001; 158: 360-369. doi:10.1176/appi.ajp.158.3.360
29. Meltzer HY, Huang M. In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems. Prog Brain Res. 2008; 172: 177-197. doi:10.1016/S0079-6123(08)00909-6
30. Natesan S, Reckless GE, Barlow KB, Nobrega JN, Kapur S. Amisulpride the 'atypical' atypical antipsychotic--comparison to haloperidol, risperidone and clozapine. Schizophr Res. 2008; 105: 224-235. doi:10.1016/j.schres.2008.07.005
31. Hicks PB. The effect of serotonergic agents on haloperidol-induced catalepsy. Life Sci. 1990; 47: 1609-1615. doi:10.1016/0024-3205(90)90365-X
32. He H, Richardson JS. A pharmacological, pharmacokinetic and clinical overview of risperidone, a new antipsychotic that blocks serotonin 5-HT2 and dopamine D2 receptors. Int Clin Psychopharmacol. 1995; 10: 19-30. doi:10.1097/00004850-199503000-00003
33. Gogos A, Bogeski M, van den Buuse M. Role of serotonin1A receptors in the action of antipsychotic drugs: comparison of prepulse inhibition studies in mice and rats and relevance for human pharmacology. Behav Pharmacol. 2008; 19: 548-561. doi:10.1097/FBP.0b013e32830cd822
34. Samad N, Batool F, Haleem DJ. Neurochemical and behavioral effects of 8-OH-DPAT following exposure to restraint stress in rats. Pharmacol Rep. 2007; 59: 173-180. PMid:17556795
35. Haleem DJ, Samad N, Haleem MA. Reversal of haloperidol-induced tardive vacuous chewing movements and supersensitive somatodendritic serotonergic response by buspirone in rats. Pharmacol Biochem Behav. 2007; 87: 115-121. doi:10.1016/j.pbb.2007.04.007
36. Andersson C, Hamer RM, Lawler CP, Mailman RB, Lieberman JA. Striatal volume changes in the rat following long-term administration of typical and atypical antipsychotic drugs. Neuropsychopharmacology. 2002; 27: 143-51. doi:10.1016/S0893-133X(02)00287-7